Seven Fleet Capital Management LP Acquires New Position in Zura Bio Limited $ZURA

Seven Fleet Capital Management LP purchased a new position in shares of Zura Bio Limited (NASDAQ:ZURA) in the fourth quarter, Holdings Channel.com reports. The fund purchased 166,500 shares of the company’s stock, valued at approximately $872,000. Zura Bio makes up approximately 0.7% of Seven Fleet Capital Management LP’s portfolio, making the stock its 28th largest position.

Other institutional investors have also added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in Zura Bio in the fourth quarter valued at about $348,000. Suvretta Capital Management LLC lifted its stake in shares of Zura Bio by 1.7% in the fourth quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock worth $29,171,000 after acquiring an additional 94,110 shares during the period. Quadrature Capital Ltd acquired a new position in shares of Zura Bio in the fourth quarter worth approximately $192,000. Millennium Management LLC boosted its holdings in Zura Bio by 75.1% in the fourth quarter. Millennium Management LLC now owns 1,032,680 shares of the company’s stock valued at $5,411,000 after acquiring an additional 442,980 shares during the last quarter. Finally, 683 Capital Management LLC bought a new stake in Zura Bio in the fourth quarter valued at approximately $1,358,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Stock Up 3.6%

Zura Bio stock opened at $3.75 on Friday. The company has a market capitalization of $355.80 million, a PE ratio of -3.44 and a beta of 0.03. The firm’s fifty day moving average is $4.62 and its 200 day moving average is $5.23. Zura Bio Limited has a 12-month low of $1.00 and a 12-month high of $7.44.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). Sell-side analysts expect that Zura Bio Limited will post -0.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ZURA has been the subject of several analyst reports. Chardan Capital raised their price target on shares of Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. Oppenheimer reduced their price objective on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Friday, March 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Wednesday, April 8th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Zura Bio presently has a consensus rating of “Moderate Buy” and an average price target of $10.75.

Zura Bio Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.